NAD+ and NMN: The Frontier of Cellular Energy Research

At the foundation of all life processes lies the production and utilization of energy. The molecule that plays a central role in this process is NAD+ (nicotinamide adenine dinucleotide). Since Arthur Harden and William John Young first recognized its existence in 1906 during their research on alcoholic fermentation, NAD+ has walked hand in hand with the history of biochemistry. In recent years, however, it has become clear that this molecule is far more than a mere coenzyme in energy metabolism -- it is a key regulator of the aging process itself. Could replenishing the declining NAD+ levels that come with age slow down aging? This hypothesis has sparked a global research race surrounding NMN (nicotinamide mononucleotide).

What Is NAD+: The Molecule That Carries Cellular Fuel

NAD+ is a coenzyme present in all eukaryotes and many prokaryotes, participating in over 500 enzymatic reactions within cells. Its primary function is the transfer of electrons in oxidation-reduction reactions, playing an indispensable role at every stage of energy production pathways including glycolysis, the TCA cycle (Krebs cycle), and oxidative phosphorylation. NAD+ accepts hydrogen ions and electrons to become reduced to NADH, which is then used for ATP synthesis in the mitochondrial electron transport chain.

However, the role of NAD+ extends far beyond energy metabolism. In 2000, Dr. Shin-ichi Imai of Washington University and Dr. Leonard Guarente of MIT discovered that NAD+ is an essential substrate for a class of longevity-related enzymes called sirtuins (Imai et al., 2000, Nature). Seven sirtuin types have been identified in mammals (SIRT1-SIRT7), with diverse functions including histone deacetylation, DNA repair, mitochondrial biogenesis, and inflammation control. Since sirtuins cannot be activated without NAD+, declining NAD+ levels directly translate to diminished sirtuin function.

Furthermore, NAD+ is essential for the DNA repair activity of PARP (poly ADP-ribose polymerase). When DNA is damaged, PARP consumes large quantities of NAD+ to carry out repairs. As DNA damage accumulates with age, PARP's NAD+ consumption increases, further reducing the NAD+ available for sirtuins -- creating a vicious cycle. Combined with degradation by CD38 (discussed below), NAD+ depletion has come to be regarded as one of the central mechanisms of aging.

The Science Behind Age-Related NAD+ Decline

The finding that human NAD+ levels decline markedly with age has been confirmed by multiple independent studies. Research by Massudi et al. (2012) reported that NAD+ levels in human skin tissue decrease linearly with age, dropping to approximately 50% of youthful levels by the 50s compared to the 20s. Zhu et al. (2015) confirmed a similar trend in human brain tissue.

The enzyme attracting the most attention as a primary driver of NAD+ decline is CD38, whose expression increases with age. In 2016, Dr. Eduardo Chini and colleagues at the Mayo Clinic published a paper in Cell Metabolism demonstrating that CD38 expression and activity were markedly elevated in the tissues of aged mice (Camacho-Pereira et al., 2016). CD38 possesses NADase activity that degrades NAD+, and its increase was closely linked to declining NAD+ levels, impaired mitochondrial function, and metabolic abnormalities. In CD38 knockout mice, age-related NAD+ decline was substantially attenuated, suggesting that CD38 is a major driving factor behind NAD+ depletion.

NAD+ decline is directly coupled to mitochondrial dysfunction. Gomes et al. (2013) reported in Cell that NAD+ decline attenuates SIRT1 activity, leading to the accumulation of HIF-1alpha and reduced mitochondrial energy production capacity. This NAD+ to SIRT1 to mitochondria axis was termed "pseudohypoxia" and has been widely accepted as the molecular basis for age-related decline in energy metabolism. Rajman et al. (2018) discussed in a comprehensive review in Cell Metabolism the potential for NAD+ supplementation to reverse this pseudohypoxic state and restore mitochondrial function.

The Current State of NMN Clinical Trials

NAD+ is a large molecule that, when taken orally, is not efficiently absorbed into cells in its intact form. This led to the focus on NAD+ precursors: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). NMN is converted to NAD+ within cells by the enzyme NMNAT. In 2011, an NMN-specific transporter called Slc12a8 was identified in the small intestine (Grozio et al., 2019, Nature Metabolism), clarifying the oral absorption pathway for NMN.

In 2021, Dr. Jun Yoshino and colleagues at Washington University published the results of the first large-scale human NMN clinical trial in Science (Yoshino et al., 2021). This double-blind RCT involving 25 overweight and obese postmenopausal women found that 10 weeks of oral NMN supplementation at 250 mg/day improved skeletal muscle insulin sensitivity by approximately 25%. This was the first evidence that NMN can significantly improve metabolic parameters in humans. However, no significant changes were observed in plasma NAD+ levels or body composition.

In Japan, a group centered at Keio University has conducted multiple clinical trials to verify the safety and efficacy of NMN. A Phase I trial by Irie et al. (2020) confirmed that oral NMN supplementation up to 500 mg/day is safe in humans. Yi et al. (2022) reported in Science that in an RCT of 80 healthy adults aged 40-65, the NMN group (300 mg/day for 60 days) showed significant improvements in walking speed and grip strength compared to controls. In China, a large-scale RCT involving 1,000 participants is underway, and validation of long-term safety and multi-organ effects is anticipated.

NR vs. NMN: The Precursor Debate

Alongside NMN, the other NAD+ precursor attracting significant attention is NR (nicotinamide riboside). NR has been commercialized by ChromaDex under the brand name "Niagen," while Elysium Health sells a product called "Basis" that combines NR with pterostilbene. NR was rediscovered as an NAD+ precursor vitamin by Dr. Charles Brenner in 2004 (Bieganowski & Brenner, 2004) and is converted to NAD+ via the NR kinase (NRK1/NRK2) pathway.

Comparing the bioavailability of NR and NMN is a crucial point of discussion. Trammell et al. (2016) reported in Nature Communications that oral NR administration in humans raised blood NAD+ levels by 2.7-fold. Meanwhile, NMN was long thought to be broken down into NR before absorption, but the discovery of the Slc12a8 transporter by Grozio et al. (2019) demonstrated a pathway for direct NMN absorption from the small intestine. However, the extent of this pathway's contribution in humans remains under debate.

At present, there is insufficient evidence to definitively conclude which is the "superior" NAD+ precursor. Both have been shown to raise blood NAD+ levels in multiple RCTs, but no large-scale trial has yet conclusively demonstrated clinically meaningful health outcome improvements. Dr. Brenner advocates for the superiority of NR from the standpoint of ChromaDex, the company he co-founded, while Dr. David Sinclair has publicly disclosed that he personally takes NMN. The intersection of researchers and commercial interests is one factor complicating the scientific assessment of this field.

Challenges and Outlook: The Limitations of Supplements

The greatest challenge facing NMN and NR supplements is the lack of long-term safety data. Most existing clinical trials have treatment periods of just 10 to 12 weeks, and the safety of continuous intake over several years remains unknown. A particular concern is the possibility that elevated NAD+ levels could promote cancer cell proliferation. Cancer cells are also dependent on NAD+ for energy production, and the risk that NAD+ supplementation could accelerate tumor growth cannot be theoretically ruled out. Navas & Carnero (2021) discussed this concern in Nature Reviews Cancer.

On the regulatory front, the U.S. FDA's 2022 decision to classify NMN not as a new dietary ingredient (NDI) but as a drug candidate caused significant waves. This was because Metro International Biotech (co-founded by Dr. David Sinclair) had filed NMN as a drug candidate, and the decision could potentially restrict NMN's sale as a supplement. In 2023, the FDA reaffirmed this position and issued warning letters to several companies selling NMN products. However, this regulation is limited to the United States, and NMN remains available as a supplement in Japan, the EU, and other markets.

NAD+ precursors also exist in foods. NMN is found in broccoli (0.25-1.12 mg per 100g), edamame (0.47-1.88 mg), and avocado (0.36-1.60 mg), but achieving the typical supplement dosage (250-500 mg) through food alone is not realistic. Dr. David Sinclair has publicly disclosed taking 1,000 mg/day of NMN as a Harvard researcher and has broadly promoted NMN's benefits through podcasts and books. However, the conflict of interest with Metro International Biotech, the company he co-founded, has drawn criticism, and the blurring line between scientific evidence and personal endorsement warrants caution. NAD+ research is indeed a promising frontier of aging science, but a significant gap still exists between the marketing narrative of "rejuvenation supplements" and rigorous scientific evidence.

Back to STORIES